- cafead   Nov 12, 2024 at 09:03: PM
via AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) reported positive topline results from a Phase 3 study of their drug Koselugo in the treatment of neurofibromatosis type 1, or NF1.
article source
article source